External validation of the updated partin tables in a cohort of French and Italian men.
OBJECTIVE
To test the discrimination and calibration properties of the newly developed 2007 Partin Tables in two European cohorts with localized prostate cancer.


METHODS
Data on clinical and pathologic characteristics were obtained for 1,064 men treated with radical prostatectomy at the Creteil University Health Center in France (n = 839) and at the Milan University Vita-Salute in Italy (n = 225). Overall discrimination was assessed with receiver operating characteristic curve analysis, which quantified the accuracy of stage predictions for each center. Calibration plots graphically explored the relationship between predicted and observed rates of extracapsular extension (ECE), seminal vesicle invasion (SVI) and lymph node invasion (LNI).


RESULTS
The rates of ECE, SVI, and LNI were 28%, 14%, and 2% in the Creteil cohort vs. 11%, 5%, and 5% in the Milan cohort. In the Creteil cohort, the accuracy of ECE, SVI, and LNI prediction was 61%, 71%, and 82% vs. 66%, 92% and 75% for the Milan cohort. Important departures were recorded between Partin Tables' predicted and observed rates of ECE, SVI, and LNI within both cohorts.


CONCLUSIONS
The 2007 Partin Tables demonstrated worse performance in European men than they originally did in North American men. This indicates that predictive models need to be externally validated before their implementation into clinical practice.
Bhojani
Naeem
N
Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, PQ, Canada.
Salomon
Laurent
L
Capitanio
Umberto
U
Suardi
Nazareno
N
Shariat
Shahrokh F
SF
Jeldres
Claudio
C
Zini
Laurent
L
Pharand
Daniel
D
Péloquin
François
F
Arjane
Philippe
P
Abbou
Claude C
CC
De La Taille
Alexandre
A
Montorsi
Francesco
F
Karakiewicz
Pierre I
PI
D002138:Calibration; D015331:Cohort Studies; D005602:France; D006801:Humans; D007558:Italy; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging / Q000379:methods*; D010388:Pelvis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery; D012372:ROC Curve; D012669:Seminal Vesicles / Q000473:pathology*; D012680:Sensitivity and Specificity
D017430:Prostate-Specific Antigen